Brought to you by 
Investors put $93mm into Paratek as part of merger with Transcept
23 Aug 2017
Executive Summary
As part of its reverse merger with public neuroscience firm Transcept Pharmaceuticals Inc., infectious disease-focused Paratek Pharmaceuticals Inc. will receive $93mm from its current stockholders Omega Funds, HBM Healthcare Investments, and Aisling Capital; Transcept shareholders InterWest Ventures and Roumell Asset Management; and new backers The Baupost Group, Abingworth, and other institutional investors. Post-acquisition, Paratek will focus on lead compound omadacycline, a Phase III-ready oral and intravenous antibiotic.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Investors put $93mm into Paratek as part of merger with Transcept
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice